Trial · NCT01103323
Adverse events630
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 630
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Edema: Limb | Blood and lymphatic system disorders | Regorafenib (BAY73-4506)+BSC | 49 | 500 | 57 |
| other | Edema: Limb | Blood and lymphatic system disorders | Placebo+BSC | 16 | 253 | 19 |
| other | Edema: Limb | Blood and lymphatic system disorders | Placebo - Regorafenib After Unblinding | 0 | 4 | 0 |
| other | Hemoglobin | Blood and lymphatic system disorders | Regorafenib (BAY73-4506)+BSC | 76 | 500 | 142 |
| other | Hemoglobin | Blood and lymphatic system disorders | Placebo+BSC | 29 | 253 | 46 |
| other | Hemoglobin | Blood and lymphatic system disorders | Placebo - Regorafenib After Unblinding | 0 | 4 | 0 |
| other | Platelets | Blood and lymphatic system disorders | Regorafenib (BAY73-4506)+BSC | 79 | 500 | 136 |
| other | Platelets | Blood and lymphatic system disorders | Placebo+BSC | 6 | 253 | 9 |
| other | Platelets | Blood and lymphatic system disorders | Placebo - Regorafenib After Unblinding | 1 | 4 | 2 |
| other | Hypertension | Cardiac disorders | Regorafenib (BAY73-4506)+BSC | 155 | 500 | 213 |
| other | Hypertension | Cardiac disorders | Placebo+BSC | 21 | 253 | 23 |
| other | Hypertension | Cardiac disorders | Placebo - Regorafenib After Unblinding | 1 | 4 | 1 |
| other | Hypothyroidism | Endocrine disorders | Regorafenib (BAY73-4506)+BSC | 27 | 500 | 29 |
| other | Hypothyroidism | Endocrine disorders | Placebo+BSC | 1 | 253 | 1 |
| other | Hypothyroidism | Endocrine disorders | Placebo - Regorafenib After Unblinding | 1 | 4 | 1 |
| other | Ocular - Other | Eye disorders | Regorafenib (BAY73-4506)+BSC | 5 | 500 | 5 |
| other | Ocular - Other | Eye disorders | Placebo+BSC | 0 | 253 | 0 |
| other | Ocular - Other | Eye disorders | Placebo - Regorafenib After Unblinding | 1 | 4 | 1 |
| other | Anorexia | Gastrointestinal disorders | Regorafenib (BAY73-4506)+BSC | 239 | 500 | 388 |
| other | Anorexia | Gastrointestinal disorders | Placebo+BSC | 73 | 253 | 96 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01103323/events